Effect observation of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the treatment of advanced NSCLC
- VernacularTitle:康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌的效果观察
- Author:
Xiaoxiao ZHANG
1
;
Zhiwei ZHANG
1
;
Xiaoqian DONG
1
;
Manli XIE
1
;
Wanli DENG
1
;
Ming ZHANG
1
Author Information
1. Dept. of TCM Oncology，Putuo Hospital，Shanghai University of Traditional Chinese Medicine，Shanghai 200062，China
- Publication Type:Journal Article
- Keywords:
Kanglaite injection;
camrelizumab;
combination chemotherapy;
non-small cell lung cancer;
clinical efficacy
- From:
China Pharmacy
2024;35(15):1882-1887
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the clinical efficacy of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer （NSCLC）. METHODS A total of 192 patients with advanced NSCLC and hospitalized in the TCM oncology department of our hospital from January 1st， 2018 to December 1st， 2022 were retrospectively selected as the study objects， and were divided into observation group （additional use， n＝104） and control group （without additional use， n＝88） according to whether the patients additionally received Kanglaite injection based on camrelizumab combined with chemotherapy （carboplatin+pemetrexed）. The short-term therapeutic effects of 2，4 and 6 cycles were compared between the two groups. The levels of peripheral blood immune function indexes and serum tumor markers were compared before treatment， after 3 cycles of treatment and after treatment. The long-term therapeutic effects as well as the occurrence of adverse drug reaction（ADR） during hospitalization were compared between the two groups. RESULTS After 3 treatment cycles and at the end of treatment， the CD4+ T lymphocyte ratio and CD4+/CD8+ in the observation group were notably greater than the control group （P＜0.05）； the levels of serum carcinoembryonic antigen and cytokeratin 19 fragment antigen 21-1 were significantly lower than those in the control group （P＜0.05）. The overall survival of the observation group was significantly longer than that of the control group （P＜0.05）， and the median overall survival was （185.27±38.21） d and （132.11±34.23） d， respectively. There were no significant differences in the whole ADR and grade ≥3 ADR between the two groups during hospitalization（P＞0.05）. CONCLUSIONS Based on camrelizumab combined with chemotherapy， the addition of Kanglaite injection can enhance immunological response and prolong overall survival in advanced NSCLC patients.
